SrasV1, PubMed, Curation, bibRecord, 001484

Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.

Identifieur interne : 001484 ( PubMed/Curation ); précédent : 001483; suivant : 001485

Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.

Auteurs : Hsueh-Ling Janice Oh [Singapour] ; Adeline Chia ; Cynthia Xin Lei Chang ; Hoe Nam Leong ; Khoon Lin Ling ; Gijsbert M. Grotenbreg ; Adam J. Gehring ; Yee Joo Tan ; Antonio Bertoletti

Source :

Journal of virology [ 1098-5514 ] ; 2011.

RBID : pubmed:21813600

Descripteurs français

English descriptors

KwdEn :
- CD4-Positive T-Lymphocytes (immunology), CD8-Positive T-Lymphocytes (immunology), Cell Degranulation, Chemokine CCL3 (metabolism), Chemokine CCL4 (metabolism), Epitopes, T-Lymphocyte (immunology), Genetic Engineering, Humans, Immunodominant Epitopes (immunology), Immunologic Memory, Interferon-gamma (metabolism), Receptors, Antigen, T-Cell (genetics), SARS Virus (immunology), Tumor Necrosis Factor-alpha (metabolism).
MESH :
- chemical , genetics : Receptors, Antigen, T-Cell.
- chemical , immunology : Epitopes, T-Lymphocyte, Immunodominant Epitopes.
- chemical , metabolism : Chemokine CCL3, Chemokine CCL4, Interferon-gamma, Tumor Necrosis Factor-alpha.
- immunology : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, SARS Virus.
- Cell Degranulation, Genetic Engineering, Humans, Immunologic Memory.

Abstract

Severe acute respiratory syndrome (SARS) is a highly contagious and life threatening disease, with a fatality rate of almost 10%. The etiologic agent is a novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), with animal reservoirs found in bats and other wild animals and thus the possibility of reemergence. In this study, we first investigated at 6 years postinfection whether SARS-specific memory T cells persist in SARS-recovered individuals, demonstrating that these subjects still possess polyfunctional SARS-specific memory CD4+ and CD8+ T cells. A dominant memory CD8+ T cell response against SARS-CoV nucleocaspid protein (NP; amino acids 216 to 225) was then defined in SARS-recovered individuals carrying HLA-B*40:01, a HLA-B molecule present in approximately one-quarter of subjects of Asian ethnicities. To reconstitute such a CD8+ T cell response, we isolated the alpha and beta T cell receptors of the HLA-B*40:01-restricted SARS-specific CD8+ T cells. Using T cell receptor gene transfer, we generated SARS-specific redirected T cells from the lymphocytes of normal individuals. These engineered CD8+ T cells displayed avidity and functionality similar to that of natural SARS-specific memory CD8+ T cells. They were able to degranulate and produce gamma interferon, tumor necrosis factor alpha, and macrophage inflammatory proteins 1α and 1β after antigenic stimulation. Since there is no effective treatment against SARS, these transduced T cells specific for an immunodominant SARS epitope may provide a new avenue for treatment during a SARS outbreak.

DOI: 10.1128/JVI.05039-11
PubMed: 21813600

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001484

Links to Exploration step

pubmed:21813600

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.</title>
<author><name sortKey="Oh, Hsueh Ling Janice" sort="Oh, Hsueh Ling Janice" uniqKey="Oh H" first="Hsueh-Ling Janice" last="Oh">Hsueh-Ling Janice Oh</name>
<affiliation wicri:level="1"><nlm:affiliation>Collaborative Anti-Viral Research Group, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Collaborative Anti-Viral Research Group, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chia, Adeline" sort="Chia, Adeline" uniqKey="Chia A" first="Adeline" last="Chia">Adeline Chia</name>
</author>
<author><name sortKey="Chang, Cynthia Xin Lei" sort="Chang, Cynthia Xin Lei" uniqKey="Chang C" first="Cynthia Xin Lei" last="Chang">Cynthia Xin Lei Chang</name>
</author>
<author><name sortKey="Leong, Hoe Nam" sort="Leong, Hoe Nam" uniqKey="Leong H" first="Hoe Nam" last="Leong">Hoe Nam Leong</name>
</author>
<author><name sortKey="Ling, Khoon Lin" sort="Ling, Khoon Lin" uniqKey="Ling K" first="Khoon Lin" last="Ling">Khoon Lin Ling</name>
</author>
<author><name sortKey="Grotenbreg, Gijsbert M" sort="Grotenbreg, Gijsbert M" uniqKey="Grotenbreg G" first="Gijsbert M" last="Grotenbreg">Gijsbert M. Grotenbreg</name>
</author>
<author><name sortKey="Gehring, Adam J" sort="Gehring, Adam J" uniqKey="Gehring A" first="Adam J" last="Gehring">Adam J. Gehring</name>
</author>
<author><name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee Joo" last="Tan">Yee Joo Tan</name>
</author>
<author><name sortKey="Bertoletti, Antonio" sort="Bertoletti, Antonio" uniqKey="Bertoletti A" first="Antonio" last="Bertoletti">Antonio Bertoletti</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2011">2011</date>
<idno type="RBID">pubmed:21813600</idno>
<idno type="pmid">21813600</idno>
<idno type="doi">10.1128/JVI.05039-11</idno>
<idno type="wicri:Area/PubMed/Corpus">001484</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001484</idno>
<idno type="wicri:Area/PubMed/Curation">001484</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001484</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.</title>
<author><name sortKey="Oh, Hsueh Ling Janice" sort="Oh, Hsueh Ling Janice" uniqKey="Oh H" first="Hsueh-Ling Janice" last="Oh">Hsueh-Ling Janice Oh</name>
<affiliation wicri:level="1"><nlm:affiliation>Collaborative Anti-Viral Research Group, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore.</nlm:affiliation>
<country xml:lang="fr">Singapour</country>
<wicri:regionArea>Collaborative Anti-Viral Research Group, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Chia, Adeline" sort="Chia, Adeline" uniqKey="Chia A" first="Adeline" last="Chia">Adeline Chia</name>
</author>
<author><name sortKey="Chang, Cynthia Xin Lei" sort="Chang, Cynthia Xin Lei" uniqKey="Chang C" first="Cynthia Xin Lei" last="Chang">Cynthia Xin Lei Chang</name>
</author>
<author><name sortKey="Leong, Hoe Nam" sort="Leong, Hoe Nam" uniqKey="Leong H" first="Hoe Nam" last="Leong">Hoe Nam Leong</name>
</author>
<author><name sortKey="Ling, Khoon Lin" sort="Ling, Khoon Lin" uniqKey="Ling K" first="Khoon Lin" last="Ling">Khoon Lin Ling</name>
</author>
<author><name sortKey="Grotenbreg, Gijsbert M" sort="Grotenbreg, Gijsbert M" uniqKey="Grotenbreg G" first="Gijsbert M" last="Grotenbreg">Gijsbert M. Grotenbreg</name>
</author>
<author><name sortKey="Gehring, Adam J" sort="Gehring, Adam J" uniqKey="Gehring A" first="Adam J" last="Gehring">Adam J. Gehring</name>
</author>
<author><name sortKey="Tan, Yee Joo" sort="Tan, Yee Joo" uniqKey="Tan Y" first="Yee Joo" last="Tan">Yee Joo Tan</name>
</author>
<author><name sortKey="Bertoletti, Antonio" sort="Bertoletti, Antonio" uniqKey="Bertoletti A" first="Antonio" last="Bertoletti">Antonio Bertoletti</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="eISSN">1098-5514</idno>
<imprint><date when="2011" type="published">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>CD4-Positive T-Lymphocytes (immunology)</term>
<term>CD8-Positive T-Lymphocytes (immunology)</term>
<term>Cell Degranulation</term>
<term>Chemokine CCL3 (metabolism)</term>
<term>Chemokine CCL4 (metabolism)</term>
<term>Epitopes, T-Lymphocyte (immunology)</term>
<term>Genetic Engineering</term>
<term>Humans</term>
<term>Immunodominant Epitopes (immunology)</term>
<term>Immunologic Memory</term>
<term>Interferon-gamma (metabolism)</term>
<term>Receptors, Antigen, T-Cell (genetics)</term>
<term>SARS Virus (immunology)</term>
<term>Tumor Necrosis Factor-alpha (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Chimiokine CCL3 (métabolisme)</term>
<term>Chimiokine CCL4 (métabolisme)</term>
<term>Dégranulation cellulaire</term>
<term>Déterminants antigéniques des lymphocytes T (immunologie)</term>
<term>Facteur de nécrose tumorale alpha (métabolisme)</term>
<term>Génie génétique</term>
<term>Humains</term>
<term>Interféron gamma (métabolisme)</term>
<term>Lymphocytes T CD4+ (immunologie)</term>
<term>Lymphocytes T CD8+ (immunologie)</term>
<term>Mémoire immunologique</term>
<term>Récepteurs aux antigènes des cellules T (génétique)</term>
<term>Virus du SRAS (immunologie)</term>
<term>Épitopes immunodominants (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Receptors, Antigen, T-Cell</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Epitopes, T-Lymphocyte</term>
<term>Immunodominant Epitopes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Chemokine CCL3</term>
<term>Chemokine CCL4</term>
<term>Interferon-gamma</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Récepteurs aux antigènes des cellules T</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Déterminants antigéniques des lymphocytes T</term>
<term>Lymphocytes T CD4+</term>
<term>Lymphocytes T CD8+</term>
<term>Virus du SRAS</term>
<term>Épitopes immunodominants</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term>
<term>CD8-Positive T-Lymphocytes</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Chimiokine CCL3</term>
<term>Chimiokine CCL4</term>
<term>Facteur de nécrose tumorale alpha</term>
<term>Interféron gamma</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Cell Degranulation</term>
<term>Genetic Engineering</term>
<term>Humans</term>
<term>Immunologic Memory</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Dégranulation cellulaire</term>
<term>Génie génétique</term>
<term>Humains</term>
<term>Mémoire immunologique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is a highly contagious and life threatening disease, with a fatality rate of almost 10%. The etiologic agent is a novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), with animal reservoirs found in bats and other wild animals and thus the possibility of reemergence. In this study, we first investigated at 6 years postinfection whether SARS-specific memory T cells persist in SARS-recovered individuals, demonstrating that these subjects still possess polyfunctional SARS-specific memory CD4+ and CD8+ T cells. A dominant memory CD8+ T cell response against SARS-CoV nucleocaspid protein (NP; amino acids 216 to 225) was then defined in SARS-recovered individuals carrying HLA-B*40:01, a HLA-B molecule present in approximately one-quarter of subjects of Asian ethnicities. To reconstitute such a CD8+ T cell response, we isolated the alpha and beta T cell receptors of the HLA-B*40:01-restricted SARS-specific CD8+ T cells. Using T cell receptor gene transfer, we generated SARS-specific redirected T cells from the lymphocytes of normal individuals. These engineered CD8+ T cells displayed avidity and functionality similar to that of natural SARS-specific memory CD8+ T cells. They were able to degranulate and produce gamma interferon, tumor necrosis factor alpha, and macrophage inflammatory proteins 1α and 1β after antigenic stimulation. Since there is no effective treatment against SARS, these transduced T cells specific for an immunodominant SARS epitope may provide a new avenue for treatment during a SARS outbreak.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21813600</PMID>
<DateCompleted><Year>2011</Year>
<Month>11</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>85</Volume>
<Issue>20</Issue>
<PubDate><Year>2011</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.</ArticleTitle>
<Pagination><MedlinePgn>10464-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.05039-11</ELocationID>
<Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is a highly contagious and life threatening disease, with a fatality rate of almost 10%. The etiologic agent is a novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV), with animal reservoirs found in bats and other wild animals and thus the possibility of reemergence. In this study, we first investigated at 6 years postinfection whether SARS-specific memory T cells persist in SARS-recovered individuals, demonstrating that these subjects still possess polyfunctional SARS-specific memory CD4+ and CD8+ T cells. A dominant memory CD8+ T cell response against SARS-CoV nucleocaspid protein (NP; amino acids 216 to 225) was then defined in SARS-recovered individuals carrying HLA-B*40:01, a HLA-B molecule present in approximately one-quarter of subjects of Asian ethnicities. To reconstitute such a CD8+ T cell response, we isolated the alpha and beta T cell receptors of the HLA-B*40:01-restricted SARS-specific CD8+ T cells. Using T cell receptor gene transfer, we generated SARS-specific redirected T cells from the lymphocytes of normal individuals. These engineered CD8+ T cells displayed avidity and functionality similar to that of natural SARS-specific memory CD8+ T cells. They were able to degranulate and produce gamma interferon, tumor necrosis factor alpha, and macrophage inflammatory proteins 1α and 1β after antigenic stimulation. Since there is no effective treatment against SARS, these transduced T cells specific for an immunodominant SARS epitope may provide a new avenue for treatment during a SARS outbreak.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oh</LastName>
<ForeName>Hsueh-Ling Janice</ForeName>
<Initials>HL</Initials>
<AffiliationInfo><Affiliation>Collaborative Anti-Viral Research Group, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chia</LastName>
<ForeName>Adeline</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chang</LastName>
<ForeName>Cynthia Xin Lei</ForeName>
<Initials>CX</Initials>
</Author>
<Author ValidYN="Y"><LastName>Leong</LastName>
<ForeName>Hoe Nam</ForeName>
<Initials>HN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ling</LastName>
<ForeName>Khoon Lin</ForeName>
<Initials>KL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Grotenbreg</LastName>
<ForeName>Gijsbert M</ForeName>
<Initials>GM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gehring</LastName>
<ForeName>Adam J</ForeName>
<Initials>AJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tan</LastName>
<ForeName>Yee Joo</ForeName>
<Initials>YJ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bertoletti</LastName>
<ForeName>Antonio</ForeName>
<Initials>A</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>08</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054405">Chemokine CCL3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054407">Chemokine CCL4</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016056">Immunodominant Epitopes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011948">Receptors, Antigen, T-Cell</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015550" MajorTopicYN="N">Cell Degranulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054405" MajorTopicYN="N">Chemokine CCL3</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054407" MajorTopicYN="N">Chemokine CCL4</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005818" MajorTopicYN="N">Genetic Engineering</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016056" MajorTopicYN="N">Immunodominant Epitopes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011948" MajorTopicYN="N">Receptors, Antigen, T-Cell</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>8</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2011</Year>
<Month>11</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">21813600</ArticleId>
<ArticleId IdType="pii">JVI.05039-11</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.05039-11</ArticleId>
<ArticleId IdType="pmc">PMC3187484</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2002 Apr 1;99(7):2592-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11895798</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2004 Jun;78(11):5612-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15140958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2004 Jul 1;104(1):200-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15016646</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Today. 1999 May;20(5):212-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10322299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiol Mol Biol Rev. 2005 Dec;69(4):635-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16339739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2006 Apr 12;24(16):3100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16494977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2006 May 26;344(1):63-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16630549</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2006 Jun 15;107(12):4781-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16467198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2006 Aug 1;351(2):466-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16690096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2006 Aug 15;177(4):2138-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16887973</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2006;1:e24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17183651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2007 Jun 11;204(6):1405-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17535971</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W503-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18503082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2008 Oct 15;181(8):5490-500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18832706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Nov;82(22):10986-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18799575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Virol. 2009;154(7):1093-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19526193</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Immunol. 2009;10:61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19958537</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2010 Jan;38(Database issue):D854-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19906713</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Feb;84(3):1289-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19906920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2010;6(7):e1001018</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20686664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol. 2010 Sep;136(3):338-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20547105</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2010 Sep;84(18):9318-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20610717</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2010 Oct 15;202(8):1171-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20831383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2010 Nov 18;116(20):4360-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20625005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nucleic Acids Res. 2011 Jan;39(Database issue):D913-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21062830</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hepatol. 2011 Jul;55(1):103-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21145860</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Tissue Antigens. 2001 Jan;57(1):46-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11169258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001484 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001484 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:21813600
   |texte=   Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:21813600" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.

Engineering T cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki